231 related articles for article (PubMed ID: 34632580)
21. The use of rituximab to prevent severe delayed haemolytic transfusion reaction in immunized patients with sickle cell disease.
Noizat-Pirenne F; Habibi A; Mekontso-Dessap A; Razazi K; Chadebech P; Mahevas M; Vingert B; Bierling P; Galactéros F; Bartolucci P; Michel M
Vox Sang; 2015 Apr; 108(3):262-7. PubMed ID: 25523469
[TBL] [Abstract][Full Text] [Related]
22. Urgent use of voxelotor in sickle cell disease when immediate transfusion is not safe.
Ferlis M; Lipato T; Roseff SD; Smith WR
Eur J Haematol; 2022 Nov; 109(5):586-589. PubMed ID: 35848827
[TBL] [Abstract][Full Text] [Related]
23. Red blood cell alloimmunization and minor red blood cell antigen phenotypes in transfused Ghanaian patients with sickle cell disease.
Boateng LA; Campbell AD; Davenport RD; Osei-Akoto A; Hugan S; Asamoah A; Schonewille H
Transfusion; 2019 Jun; 59(6):2016-2022. PubMed ID: 30758856
[TBL] [Abstract][Full Text] [Related]
24. Preventing antibody positive delayed hemolytic transfusion reactions in sickle cell disease: Lessons learned from a case.
Rankin A; Webb J; Nickel RS
Transfus Med; 2022 Oct; 32(5):433-436. PubMed ID: 35318744
[TBL] [Abstract][Full Text] [Related]
25. Early occurrence of red blood cell alloimmunization in patients with sickle cell disease.
Sins JW; Biemond BJ; van den Bersselaar SM; Heijboer H; Rijneveld AW; Cnossen MH; Kerkhoffs JL; van Meurs AH; von Ronnen FB; Zalpuri S; de Rijke YB; Ellen van der Schoot C; de Haas M; van der Bom JG; Fijnvandraat K
Am J Hematol; 2016 Aug; 91(8):763-9. PubMed ID: 27102719
[TBL] [Abstract][Full Text] [Related]
26. Delayed hemolytic transfusion reaction in sickle cell disease patients: evidence of an emerging syndrome with suicidal red blood cell death.
Chadebech P; Habibi A; Nzouakou R; Bachir D; Meunier-Costes N; Bonin P; Rodet M; Chami B; Galacteros F; Bierling P; Noizat-Pirenne F
Transfusion; 2009 Sep; 49(9):1785-92. PubMed ID: 19413729
[TBL] [Abstract][Full Text] [Related]
27. The cause and pathogenesis of hemolytic transfusion reactions in sickle-cell disease.
Pirenne F
Curr Opin Hematol; 2019 Nov; 26(6):488-494. PubMed ID: 31589171
[TBL] [Abstract][Full Text] [Related]
28. Red blood cell alloimmunization and delayed hemolytic transfusion reactions in patients with sickle cell disease.
Balbuena-Merle R; Hendrickson JE
Transfus Clin Biol; 2019 May; 26(2):112-115. PubMed ID: 30857806
[TBL] [Abstract][Full Text] [Related]
29. Successful Outcome of Hyperhemolysis in Sickle Cell Disease following Multiple Lines of Treatment: The Role of Complement Inhibition.
Vlachaki E; Gavriilaki E; Kafantari K; Adamidou D; Tsitsikas D; Chasapopoulou E; Anagnostopoulos A; Tsapas A
Hemoglobin; 2018; 42(5-6):339-341. PubMed ID: 30626228
[TBL] [Abstract][Full Text] [Related]
30. Delayed hemolytic transfusion reactions in sickle cell disease: simultaneous destruction of recipients' red cells.
King KE; Shirey RS; Lankiewicz MW; Young-Ramsaran J; Ness PM
Transfusion; 1997 Apr; 37(4):376-81. PubMed ID: 9111274
[TBL] [Abstract][Full Text] [Related]
31. Transfusion management of sickle cell patients during bone marrow transplantation with matched sibling donor.
McPherson ME; Anderson AR; Haight AE; Jessup P; Castillejo MI; Hillyer CD; Josephson CD
Transfusion; 2009 Sep; 49(9):1977-86. PubMed ID: 19453984
[TBL] [Abstract][Full Text] [Related]
32. Cytokine changes in sickle-cell disease patients as markers predictive of the onset of delayed hemolytic transfusion reactions.
Chadebech P; de Ménorval MA; Bodivit G; Jouard A; Pakdaman S; Lelong F; Habibi A; Galactéros F; Lecron JC; Pirenne F
Cytokine; 2020 Dec; 136():155259. PubMed ID: 32920319
[TBL] [Abstract][Full Text] [Related]
33. Catastrophic Delayed Hemolytic Transfusion Reaction in a Patient With Sickle Cell Disease Without Alloantibodies: Case Report and Review of Literature.
Jasinski S; Glasser CL
J Pediatr Hematol Oncol; 2019 Nov; 41(8):624-626. PubMed ID: 30179992
[TBL] [Abstract][Full Text] [Related]
34. Mechanisms of alloimmunization in sickle cell disease.
Hudson KE; Fasano RM; Karafin MS; Hendrickson JE; Francis RO
Curr Opin Hematol; 2019 Nov; 26(6):434-441. PubMed ID: 31483335
[TBL] [Abstract][Full Text] [Related]
35. Prospective RBC phenotype matching in a stroke-prevention trial in sickle cell anemia: a multicenter transfusion trial.
Vichinsky EP; Luban NL; Wright E; Olivieri N; Driscoll C; Pegelow CH; Adams RJ;
Transfusion; 2001 Sep; 41(9):1086-92. PubMed ID: 11552063
[TBL] [Abstract][Full Text] [Related]
36. Immune erythrocyte antibodies in adult patients with sickle cell disease and blood donors in Lagos, Nigeria: a comparative study.
Adewoyin AS; Daramola OA; Ogbenna AA; Adeyemo TA
Immunohematology; 2021 Sep; 37(3):131-137. PubMed ID: 34591378
[TBL] [Abstract][Full Text] [Related]
37. Clinical presentation of delayed hemolytic transfusion reactions and hyperhemolysis in sickle cell disease.
Fasano RM; Miller MJ; Chonat S; Stowell SR
Transfus Clin Biol; 2019 May; 26(2):94-98. PubMed ID: 30837199
[TBL] [Abstract][Full Text] [Related]
38. Decreasing alloimmunization-specific mortality in sickle cell disease in the United States: Cost-effectiveness of a shared transfusion resource.
Ito S; Pandya A; Hauser RG; Krishnamurti L; Stites E; Tormey C; Krumholz HM; Hendrickson JE; Goshua G
Am J Hematol; 2024 Apr; 99(4):570-576. PubMed ID: 38279581
[TBL] [Abstract][Full Text] [Related]
39. Utilising red cell antigen genotyping and serological phenotyping in sickle cell disease patients to risk-stratify patients for alloimmunisation risk.
Shih AW; Yan MTS; Elahie AL; Barty RL; Liu Y; Berardi P; Azzam M; Siddiqui R; Parvizian MK; Mcdougall T; Heddle NM; Al-Habsi KS; Goldman M; Cote J; Athale U; Verhovsek MM
Transfus Med; 2020 Aug; 30(4):263-274. PubMed ID: 32432400
[TBL] [Abstract][Full Text] [Related]
40. Delayed hemolytic transfusion reaction in the French hemovigilance system.
Rieux C; Brittenham G; Bachir D; De Meyer E; Boudjedir K;
Transfus Clin Biol; 2019 May; 26(2):109-111. PubMed ID: 30910456
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
